Protagenic Therapeutics (OTCMKTS:PTIX) and Nielsen (NYSE:NLSN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Valuation and Earnings
This table compares Protagenic Therapeutics and Nielsen’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Protagenic Therapeutics||N/A||N/A||-$2.25 million||N/A||N/A|
|Nielsen||$6.57 billion||1.42||$429.00 million||$2.11||12.46|
Nielsen has higher revenue and earnings than Protagenic Therapeutics.
Volatility and Risk
Protagenic Therapeutics has a beta of -9.02, meaning that its share price is 1,002% less volatile than the S&P 500. Comparatively, Nielsen has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Nielsen pays an annual dividend of $1.40 per share and has a dividend yield of 5.3%. Protagenic Therapeutics does not pay a dividend. Nielsen pays out 66.4% of its earnings in the form of a dividend. Nielsen has raised its dividend for 5 consecutive years.
This is a breakdown of recent recommendations and price targets for Protagenic Therapeutics and Nielsen, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Nielsen has a consensus target price of $28.00, indicating a potential upside of 6.46%. Given Nielsen’s higher possible upside, analysts plainly believe Nielsen is more favorable than Protagenic Therapeutics.
This table compares Protagenic Therapeutics and Nielsen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Nielsen beats Protagenic Therapeutics on 10 of the 11 factors compared between the two stocks.
Protagenic Therapeutics Company Profile
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
Nielsen Company Profile
Nielsen Holdings plc, together with its subsidiaries, operates as an information and measurement company. It operates through Buy and Watch segments. The company provides media and marketing information, analytics, and manufacturer and retailer expertise about what and where consumers buy, read, watch, and listen. The Buy segment provides retail transactional measurement data, consumer behavior information, and analytics primarily to businesses in the consumer packaged goods industry. This segment provides data on retail measurement services, such as market share and competitive sales volumes; insights into distribution, pricing, merchandising, and promotion; consumer panel measurement, which offers insight into shopper behavior and customer segmentation; and consumer intelligence and analytical services for decision making in product development and marketing cycles. The Watch segment provides viewership and listening data, and analytics primarily to the media and advertising industries for television, radio, print, online, and mobile viewing, and listening platforms. This segment offers television audience measurement services; audio audience measurement services; digital audience measurement services, such as digital media and market research, audience analytics, and social media measurement; mobile measurement services comprising measurement and consumer research for telecom and media companies; and total audience measurement services, as well as advertising solutions. The company was formerly known as Nielsen N.V. and changed its name to Nielsen Holdings plc in August 2015. Nielsen Holdings plc has a strategic alliance with Microsoft Corporation to develop solutions for the fast-moving consumer goods and retail companies. The company was founded in 1923 and is headquartered in New York, New York.
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.